[{"id":"a20a18eb-f6bc-4aba-a012-ed6de32b0684","acronym":"","url":"https://clinicaltrials.gov/study/NCT02772822","created_at":"2021-01-18T13:35:43.504Z","updated_at":"2024-07-02T16:37:32.151Z","phase":"Phase 3","brief_title":"A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients","source_id_and_acronym":"NCT02772822","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Anpingxi (ripertamab) • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 330","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2016-05-16"}]